Innate Pharma (IPHA) FCF Margin (2020 - 2024)

Innate Pharma has reported FCF Margin for 5 years, with the latest figure at 51.54% in Q4 2024.

• For the quarter ending Q4 2024, FCF Margin rose 1052.0% year-over-year to 51.54%; the trailing twelve-month figure through Dec 2024 stood at 46.04% (down 1002.0% YoY), and the FY2025 full-year result was 1892.9%, down 185668.0% from the prior year.
• FCF Margin for Q4 2024 stood at 51.54%, up from 62.06% in the prior quarter.
• The five-year high for FCF Margin was 3.13% in Q2 2022, with the low at 232.88% in Q4 2021.
• Historically, FCF Margin has averaged 71.11% across 5 years, with a median of 51.54% in 2024.
• Annual changes were most pronounced in 2021 — FCF Margin plunged 14231 bps — and 2022, when it surged 20059 bps.
• Innate Pharma's FCF Margin stood at 90.57% in 2020, then plunged by 157 bps to 232.88% in 2021, then surged by 86 bps to 32.28% in 2022, then tumbled by 92 bps to 62.06% in 2023, then advanced by 17 bps to 51.54% in 2024.
• The last three FCF Margin figures came in at 51.54% (Q4 2024), 62.06% (Q4 2023), and 31.56% (Q2 2023), per Business Quant data.